Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma.
Identifieur interne : 004E04 ( PubMed/Curation ); précédent : 004E03; suivant : 004E05Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma.
Auteurs : M E Mcgarvey [États-Unis] ; A. Tulpule ; J. Cai ; T. Zheng ; R. Masood ; B. Espina ; N. Arora ; D L Smith ; P S GillSource :
- Current opinion in oncology [ 1040-8746 ] ; 1998.
Descripteurs français
- KwdFr :
- Angiostatines, Antinéoplasiques (usage thérapeutique), Antiviraux (usage thérapeutique), Association de médicaments, Collagène (usage thérapeutique), Endostatines, Fragments peptidiques (usage thérapeutique), Gonadotrophine chorionique (usage thérapeutique), Herpèsvirus humain de type 8 (), Infections opportunistes liées au SIDA (), Inhibiteur tissulaire des métalloprotéinases (usage thérapeutique), Plasminogène (usage thérapeutique), Sarcome de Kaposi (), Sarcome de Kaposi (virologie), Syndrome d'immunodéficience acquise (), Trétinoïne (usage thérapeutique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ().
- MESH :
- usage thérapeutique : Antinéoplasiques, Antiviraux, Collagène, Fragments peptidiques, Gonadotrophine chorionique, Inhibiteur tissulaire des métalloprotéinases, Plasminogène, Trétinoïne.
- virologie : Sarcome de Kaposi.
- Angiostatines, Association de médicaments, Endostatines, Herpèsvirus humain de type 8, Infections opportunistes liées au SIDA, Sarcome de Kaposi, Syndrome d'immunodéficience acquise, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
English descriptors
- KwdEn :
- AIDS-Related Opportunistic Infections (complications), AIDS-Related Opportunistic Infections (therapy), Acquired Immunodeficiency Syndrome (complications), Angiostatins, Antineoplastic Agents (therapeutic use), Antiviral Agents (therapeutic use), Chorionic Gonadotropin (therapeutic use), Collagen (therapeutic use), Drug Therapy, Combination, Endostatins, HIV-1 (drug effects), Herpesvirus 8, Human (drug effects), Peptide Fragments (therapeutic use), Plasminogen (therapeutic use), Sarcoma, Kaposi (complications), Sarcoma, Kaposi (therapy), Sarcoma, Kaposi (virology), Tissue Inhibitor of Metalloproteinases (therapeutic use), Tretinoin (therapeutic use).
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Antiviral Agents, Chorionic Gonadotropin, Collagen, Peptide Fragments, Plasminogen, Tissue Inhibitor of Metalloproteinases, Tretinoin.
- chemical : Angiostatins, Endostatins.
- complications : AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi.
- drug effects : HIV-1, Herpesvirus 8, Human.
- therapy : AIDS-Related Opportunistic Infections, Sarcoma, Kaposi.
- virology : Sarcoma, Kaposi.
- Drug Therapy, Combination.
Abstract
Kaposi's sarcoma (KS) is an opportunistic tumor that develops with increased frequency (100,000-fold) after HIV infection. KS causes significant morbidity from mucocutaneous involvement and mortality from complications of visceral sites of disease such as the lungs, gastrointestinal tract, and the liver. Progressive unraveling of the KS pathogenesis has lead to the development of novel therapeutic approaches. Newest therapies are first evaluated in patients with limited tumor burden. These include: 1) inhibitors of angiogenesis such as vascular endothelial growth factor signaling inhibitor (SU 5416), and several other inhibitors of angiogenesis such as the dipeptide IM 862, TNP-470, Col-3, and thalidomide; 2) topical and systemic retinoids; 3) antiviral agents specific for Kaposi's sarcoma herpesvirus and human herpesvirus-8, or HIV; and 4) pregnancy-related factors. Patients with advanced disease such as widespread mucocutaneous disease, lymphedema, and visceral disease are treated most effectively with cytotoxic agents. The most active agents include liposomal anthracyclines, paclitaxel, vinca alkaloids, and bleomycin. The combination of liposomal anthracyclines and paclitaxel, with and without the most promising biologicals, should now be studied to further reduce the toxicity, and enhance the antitumor effects. Furthermore, identification of risk factors for KS should serve to explore prophylactic therapies.
PubMed: 9800111
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004E04
Links to Exploration step
pubmed:9800111Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma.</title><author><name sortKey="Mcgarvey, M E" sort="Mcgarvey, M E" uniqKey="Mcgarvey M" first="M E" last="Mcgarvey">M E Mcgarvey</name><affiliation wicri:level="1"><nlm:affiliation>University of Southern California, Los Angeles Department of Medicine and Pathology, Norris Cancer Hospital and Research Institute 90033, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Southern California, Los Angeles Department of Medicine and Pathology, Norris Cancer Hospital and Research Institute 90033</wicri:regionArea></affiliation></author><author><name sortKey="Tulpule, A" sort="Tulpule, A" uniqKey="Tulpule A" first="A" last="Tulpule">A. Tulpule</name></author><author><name sortKey="Cai, J" sort="Cai, J" uniqKey="Cai J" first="J" last="Cai">J. Cai</name></author><author><name sortKey="Zheng, T" sort="Zheng, T" uniqKey="Zheng T" first="T" last="Zheng">T. Zheng</name></author><author><name sortKey="Masood, R" sort="Masood, R" uniqKey="Masood R" first="R" last="Masood">R. Masood</name></author><author><name sortKey="Espina, B" sort="Espina, B" uniqKey="Espina B" first="B" last="Espina">B. Espina</name></author><author><name sortKey="Arora, N" sort="Arora, N" uniqKey="Arora N" first="N" last="Arora">N. Arora</name></author><author><name sortKey="Smith, D L" sort="Smith, D L" uniqKey="Smith D" first="D L" last="Smith">D L Smith</name></author><author><name sortKey="Gill, P S" sort="Gill, P S" uniqKey="Gill P" first="P S" last="Gill">P S Gill</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9800111</idno><idno type="pmid">9800111</idno><idno type="wicri:Area/PubMed/Corpus">004E04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004E04</idno><idno type="wicri:Area/PubMed/Curation">004E04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004E04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma.</title><author><name sortKey="Mcgarvey, M E" sort="Mcgarvey, M E" uniqKey="Mcgarvey M" first="M E" last="Mcgarvey">M E Mcgarvey</name><affiliation wicri:level="1"><nlm:affiliation>University of Southern California, Los Angeles Department of Medicine and Pathology, Norris Cancer Hospital and Research Institute 90033, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Southern California, Los Angeles Department of Medicine and Pathology, Norris Cancer Hospital and Research Institute 90033</wicri:regionArea></affiliation></author><author><name sortKey="Tulpule, A" sort="Tulpule, A" uniqKey="Tulpule A" first="A" last="Tulpule">A. Tulpule</name></author><author><name sortKey="Cai, J" sort="Cai, J" uniqKey="Cai J" first="J" last="Cai">J. Cai</name></author><author><name sortKey="Zheng, T" sort="Zheng, T" uniqKey="Zheng T" first="T" last="Zheng">T. Zheng</name></author><author><name sortKey="Masood, R" sort="Masood, R" uniqKey="Masood R" first="R" last="Masood">R. Masood</name></author><author><name sortKey="Espina, B" sort="Espina, B" uniqKey="Espina B" first="B" last="Espina">B. Espina</name></author><author><name sortKey="Arora, N" sort="Arora, N" uniqKey="Arora N" first="N" last="Arora">N. Arora</name></author><author><name sortKey="Smith, D L" sort="Smith, D L" uniqKey="Smith D" first="D L" last="Smith">D L Smith</name></author><author><name sortKey="Gill, P S" sort="Gill, P S" uniqKey="Gill P" first="P S" last="Gill">P S Gill</name></author></analytic><series><title level="j">Current opinion in oncology</title><idno type="ISSN">1040-8746</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS-Related Opportunistic Infections (complications)</term><term>AIDS-Related Opportunistic Infections (therapy)</term><term>Acquired Immunodeficiency Syndrome (complications)</term><term>Angiostatins</term><term>Antineoplastic Agents (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Chorionic Gonadotropin (therapeutic use)</term><term>Collagen (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Endostatins</term><term>HIV-1 (drug effects)</term><term>Herpesvirus 8, Human (drug effects)</term><term>Peptide Fragments (therapeutic use)</term><term>Plasminogen (therapeutic use)</term><term>Sarcoma, Kaposi (complications)</term><term>Sarcoma, Kaposi (therapy)</term><term>Sarcoma, Kaposi (virology)</term><term>Tissue Inhibitor of Metalloproteinases (therapeutic use)</term><term>Tretinoin (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Angiostatines</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments</term><term>Collagène (usage thérapeutique)</term><term>Endostatines</term><term>Fragments peptidiques (usage thérapeutique)</term><term>Gonadotrophine chorionique (usage thérapeutique)</term><term>Herpèsvirus humain de type 8 ()</term><term>Infections opportunistes liées au SIDA ()</term><term>Inhibiteur tissulaire des métalloprotéinases (usage thérapeutique)</term><term>Plasminogène (usage thérapeutique)</term><term>Sarcome de Kaposi ()</term><term>Sarcome de Kaposi (virologie)</term><term>Syndrome d'immunodéficience acquise ()</term><term>Trétinoïne (usage thérapeutique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Antiviral Agents</term><term>Chorionic Gonadotropin</term><term>Collagen</term><term>Peptide Fragments</term><term>Plasminogen</term><term>Tissue Inhibitor of Metalloproteinases</term><term>Tretinoin</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Angiostatins</term><term>Endostatins</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Acquired Immunodeficiency Syndrome</term><term>Sarcoma, Kaposi</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Herpesvirus 8, Human</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Sarcoma, Kaposi</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Antiviraux</term><term>Collagène</term><term>Fragments peptidiques</term><term>Gonadotrophine chorionique</term><term>Inhibiteur tissulaire des métalloprotéinases</term><term>Plasminogène</term><term>Trétinoïne</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Sarcome de Kaposi</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Sarcoma, Kaposi</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Angiostatines</term><term>Association de médicaments</term><term>Endostatines</term><term>Herpèsvirus humain de type 8</term><term>Infections opportunistes liées au SIDA</term><term>Sarcome de Kaposi</term><term>Syndrome d'immunodéficience acquise</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Kaposi's sarcoma (KS) is an opportunistic tumor that develops with increased frequency (100,000-fold) after HIV infection. KS causes significant morbidity from mucocutaneous involvement and mortality from complications of visceral sites of disease such as the lungs, gastrointestinal tract, and the liver. Progressive unraveling of the KS pathogenesis has lead to the development of novel therapeutic approaches. Newest therapies are first evaluated in patients with limited tumor burden. These include: 1) inhibitors of angiogenesis such as vascular endothelial growth factor signaling inhibitor (SU 5416), and several other inhibitors of angiogenesis such as the dipeptide IM 862, TNP-470, Col-3, and thalidomide; 2) topical and systemic retinoids; 3) antiviral agents specific for Kaposi's sarcoma herpesvirus and human herpesvirus-8, or HIV; and 4) pregnancy-related factors. Patients with advanced disease such as widespread mucocutaneous disease, lymphedema, and visceral disease are treated most effectively with cytotoxic agents. The most active agents include liposomal anthracyclines, paclitaxel, vinca alkaloids, and bleomycin. The combination of liposomal anthracyclines and paclitaxel, with and without the most promising biologicals, should now be studied to further reduce the toxicity, and enhance the antitumor effects. Furthermore, identification of risk factors for KS should serve to explore prophylactic therapies.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9800111</PMID><DateCreated><Year>1998</Year><Month>12</Month><Day>23</Day></DateCreated><DateCompleted><Year>1998</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1040-8746</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>1998</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Current opinion in oncology</Title><ISOAbbreviation>Curr Opin Oncol</ISOAbbreviation></Journal><ArticleTitle>Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma.</ArticleTitle><Pagination><MedlinePgn>413-21</MedlinePgn></Pagination><Abstract><AbstractText>Kaposi's sarcoma (KS) is an opportunistic tumor that develops with increased frequency (100,000-fold) after HIV infection. KS causes significant morbidity from mucocutaneous involvement and mortality from complications of visceral sites of disease such as the lungs, gastrointestinal tract, and the liver. Progressive unraveling of the KS pathogenesis has lead to the development of novel therapeutic approaches. Newest therapies are first evaluated in patients with limited tumor burden. These include: 1) inhibitors of angiogenesis such as vascular endothelial growth factor signaling inhibitor (SU 5416), and several other inhibitors of angiogenesis such as the dipeptide IM 862, TNP-470, Col-3, and thalidomide; 2) topical and systemic retinoids; 3) antiviral agents specific for Kaposi's sarcoma herpesvirus and human herpesvirus-8, or HIV; and 4) pregnancy-related factors. Patients with advanced disease such as widespread mucocutaneous disease, lymphedema, and visceral disease are treated most effectively with cytotoxic agents. The most active agents include liposomal anthracyclines, paclitaxel, vinca alkaloids, and bleomycin. The combination of liposomal anthracyclines and paclitaxel, with and without the most promising biologicals, should now be studied to further reduce the toxicity, and enhance the antitumor effects. Furthermore, identification of risk factors for KS should serve to explore prophylactic therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGarvey</LastName><ForeName>M E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>University of Southern California, Los Angeles Department of Medicine and Pathology, Norris Cancer Hospital and Research Institute 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tulpule</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Masood</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Espina</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Oncol</MedlineTA><NlmUniqueID>9007265</NlmUniqueID><ISSNLinking>1040-8746</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006063">Chorionic Gonadotropin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043169">Endostatins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019714">Tissue Inhibitor of Metalloproteinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>5688UTC01R</RegistryNumber><NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance></Chemical><Chemical><RegistryNumber>86090-08-6</RegistryNumber><NameOfSubstance UI="D043168">Angiostatins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-91-6</RegistryNumber><NameOfSubstance UI="D010958">Plasminogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-34-5</RegistryNumber><NameOfSubstance UI="D003094">Collagen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017088" MajorTopicYN="N">AIDS-Related Opportunistic Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000163" MajorTopicYN="N">Acquired Immunodeficiency Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043168" MajorTopicYN="N">Angiostatins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006063" MajorTopicYN="N">Chorionic Gonadotropin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003094" MajorTopicYN="N">Collagen</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043169" MajorTopicYN="N">Endostatins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019288" MajorTopicYN="N">Herpesvirus 8, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010958" MajorTopicYN="N">Plasminogen</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012514" MajorTopicYN="N">Sarcoma, Kaposi</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019714" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinases</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>50</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>11</Month><Day>4</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>11</Month><Day>4</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9800111</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004E04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:9800111
|texte= Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:9800111" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |